Efficacy results for an experimental rheumatoid arthritis drug in development by Eli Lilly and Incyte held up well as patients in a Phase IIb trial were tracked over the course of a full year.
AstraZeneca just can't catch a break. After looking over lackluster late-stage results for its rheumatoid arthritis drug fostamatinib, the pharma giant has opted to scrap its development efforts and turn the whole program back over to Rigel, the biotech partner which had licensed it to them in the first place
European authorities have battered expectations for Pfizer's rheumatoid arthritis pill Xeljanz, spurning the drug giant's request for approval over concerns about the risk-benefit profile. The surprise rejection cools the company's run of regulatory success, which included 5 FDA approvals in 2012.
The London drug giant missed one out of two main goals for the study of fostamatinib, leaving the prospects of the candidate open to skepticism after it fell short of matching the efficacy of AbbVie's Humira in an earlier mid-stage trial.
Pfizer has quietly grabbed rights to an experimental "armed antibody" in early human testing against rheumatoid arthritis, with interest in advancing the candidate from the Italy-based biotech Philogen for inflammatory bowel disease, according to Philogen's release from yesterday.
AstraZeneca isn't the only pharma giant having problems with rheumatoid arthritis today. Eli Lilly threw in the towel on one of three Phase III studies of an experimental antibody for patients with RA after an interim analysis showed lack of efficacy.
The London-based drug giant, which has shown weakness in its late-stage pipeline this year, is pushing ahead with ongoing late-stage studies that will provide a case for regulatory submissions.
Rheumatoid arthritis drugs and anti-inflammatory medicines including Pfizer and Amgen's Enbrel and Johnson & Johnson's Remicade are profoundly effective at doing their job, but they carry an enormous risk of infection. Now scientists at the University of Utah believe they've identified a way to make a drug that is equally effective as these and other treatments but minimizes the chance of infection.
The FDA has handed Pfizer an approval for its oral rheumatoid arthritis drug tofacitinib, which will hit the market soon as Xeljanz. The news will be cheered at Pfizer, which counted the RA drug as one of its most critical late-stage programs, offering a key sign that its R&D program is back on track after years of pratfalls and disasters.
A Johnson & Johnson unit has gained a potential new weapon in the fight against rheumatoid arthritis (RA), agreeing to lay down $65 million upfront to gain rights to an oral JAK inhibitor from Astellas Pharma for all markets outside of Japan, Astellas reported.